In response to the COVID-19 pandemic, global regulatory authorities adopted a pragmatic virtual auditing approach. This approach includes the flexibility and procedural simplifications to maintain clinical trial integrity and compliance to good clinical practice (GCP) requirements, while ensuring the safety of trial participants and staff.
Prior to COVID-19, despite the digital nature of today’s world, the move to remote GCP audits and inspections remained behind the curve due to confidentiality and credibility concerns. This is now rapidly changing.
The Rising Need for Virtual Auditing
Today, increasingly more clinical trial participants are being positioned in various locations across the globe. In addition, the number of Sponsors outsourcing what were previously considered core functions continues to increase. As clinical trials continue to increase in complexity, the need for effective oversight by Sponsors is more crucial than ever before. Further complicating the matter is the drive to contain pharmaceutical development costs, which can result in shrinking budgets, reduced resources, and increased employee workloads.
These factors, along with the COVID-19 crisis, have brought a new perspective toward virtual audits and inspections by life sciences firms.
Companies are now seeing firsthand that with cloud-based computing and storage, video conferencing, screen-sharing, as well as other IT advancements, remote audits can be an efficient and effective substitute for on-site audits.
EMA and FDA Clinical Trial Guidance During COVID-19
The European Medicines Agency (EMA) and Food and Drug Administration (FDA) recently published several guidance documents regarding the conduct of clinical trial monitoring, auditing, and inspections during this pandemic period. These guidance documents have allowed all of us who work under these regulations to adapt as well. ProPharma Group’s experienced consultants are able to instantaneously adjust to the virtual auditing model, providing our clients with continuous compliance support with the requirements for self-check and monitoring oversight of clinical trials.
Both EU and US guidance prioritize trial integrity, participant safety, and privacy and maintenance of data quality as key considerations when transitioning from on-site to remote. These guidance documents advocate the use of both on-site and centralized (remote) monitoring of investigational sites as part of the Sponsor’s oversight program.
The regulatory agencies have halted on-site clinical inspections for much of the duration of the outbreak. Clinical trial compliance checks are still required, and to make them feasible, authorities in the EU and US have moved to virtual inspections and assessments.
According to EU and US guidelines, virtual auditing may be applied to all types of clinical audits. The major exception to this approach is the investigator site remote audit, especially in Europe as the EMA considers them not feasible due to local legal requirements concerning accessibility and data protection. To overcome this restriction with investigator sites, ProPharma Group offers its clients a variety of experts geographically located throughout the EU who can provide more regional and on-site support. Similarly, the EMA is currently relying on the local competent authorities of member states to perform on-site inspections using a risk-based assessment.
In contrast, FDA has been performing clinical and investigator site inspections virtually for “mission critical inspections”, while postponing other less critical inspections. Therefore, Sponsors must always be inspection ready.
Furthermore, both EMA and FDA guidelines on remote auditing foresee an impact on planned audits, and recognize that any adaptation in the planning and conduct of audits should be aligned with a risk-based assessment where all decisions are duly documented as part of a prioritization strategy. By immediately activating ProPharma Group’s business continuity plans, our consultants enabled a smooth transition to this new worldwide landscape which allowed us to support our clients and meet their auditing commitments.
Reduce Your Inspection Risk with ProPharma Group
ProPharma Group’s auditing experts are experienced in designing audit strategies that incorporate flexibility with technology tools to exceed your expectations regarding the outcome of the virtual audit process. In addition, we know how important it is to maintain a quality management system, and we can offer a range of right-sized auditing services to meet your needs.
ProPharma Group’s consultants are ready to support your company and recommend alternative approaches to systems that have been impacted by the COVID-19 pandemic, such as remote audits for the short or long-term, ensuring independent and objective evaluation of the regulatory requirements are maintained. ProPharma Group experts can help identify gaps in your documentation and processes, create action plans to mitigate noted deficiencies, and ensure inspection readiness for whenever normal operations resume.
Once the pandemic is contained, we can provide a follow up on-site audit on a risk-based schedule. In addition to being cost efficient, the adapted schedule may also free your in-house resources for other tasks deemed critical during the period of the pandemic crisis.
To learn more about ProPharma Group’s virtual audit services, contact us today.
Your Business has Complex Challenges. ProPharma Group has Exceptional Solutions.
We partner with pharmaceutical, biotechnology, and medical device clients to tackle complex challenges. Contact us to learn how our experienced team can help ensure regulatory and development success throughout the product lifecycle.
Interested in gaining an industry edge? Let us help you stay up to date.
Gain an Industry Edge With Expertise From ProPharma Group
Get the latest insights and top tips from our experts, delivered right to your inbox.
Have a complex challenge?